Changes in (A) percentages of circulating MDL-1-expressing monocytes and mRNA expresison levels of MDL-1 and DAP12, and changes in (B) disease activity score for 28-joints (DAS28) and C-reactive protein (CRP) levels in 12 RA patients at active phase (at baseline) and after 9–12 months of therapy.

<p>Data are presented as mean ± SEM. *p<0.005, versus active phase, determined by the Wilcoxon signed rank test.